Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice
Inclusion criteria
Exclusion criteria
Minamiakita, Akita, Japan
Minamitsugaru, Aomori, Japan
Awa, Chiba, Japan
Mikatakaminaka, Fukui, Japan
Kamo, Gifu, Japan
Agatsuma, Gunma, Japan
Yamagata, Hiroshima, Japan
Sorachi, Hokkaido, Japan
Kako, Hyōgo, Japan
Higashiibaraki, Ibaraki, Japan
Shimohei, Iwate, Japan
Ayauta, Kagawa-ken, Japan
Soh, Kagoshima-ken, Japan
Agawa, Kochi, Japan
Soraku, Kyoto, Japan
Chiisagata, Nagano, Japan
Hanishina, Nagano, Japan
Kamiminochi, Nagano, Japan
Shimoina, Nagano, Japan
Kitakatsuragi, Nara, Japan
Shiki, Nara, Japan
Yamatotakada, Nara, Japan
Tsukubo, Okayama-ken, Japan
Mino, Osaka, Japan
Hiki, Saitama, Japan
Kitakatsushika, Saitama, Japan
Minamisaitama, Saitama, Japan
Osato, Saitama, Japan
Gamo, Shiga, Japan
Oki, Shimane, Japan
Syuchi, Shizuoka, Japan
Tagata, Shizuoka, Japan
Bunkyo, Tokyo, Japan
Koto, Tokyo, Japan
Shinagawa, Tokyo, Japan
Suginami, Tokyo, Japan
Tohaku, Tottori, Japan
Nakaniikawa, Toyama, Japan
Shimoniikawa, Toyama, Japan
Nishimuro, Wakayama, Japan
Higashimurayama, Yamagata, Japan
Nishiokitama, Yamagata, Japan
Minamikoma, Yamanashi, Japan